Astria Therapeutics EBIT

Astria Therapeutics (ATXS) currently reports a EBIT of $-140M as of September 2025. That compares with $-100M in the prior-year period — down 35.2% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Astria Therapeutics's EBIT history and peer comparisons.

Astria Therapeutics's EBIT decreased from $-100M to $-140M — a 35.2% year-over-year decrease (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Astria Therapeutics's EBIT of $-140M is lower than the Healthcare sector average of $23B. That is roughly 100.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Astria Therapeutics reported $-140M in EBIT as of September 2025. That compares with $-100M in the prior-year period — down 35.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-140M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Astria Therapeutics, and consider following ATXS for alerts when major investors trade the stock.